Calmark leads you to a new era of point-of-care
The pressure on the health care systems increases globally and along with this comes the need of more effective healthcare. To have a first clinical assessment (triage) correctly performed is of highest importance to ensure safe healthcare.
Traditionally, a majority of the in-vitro diagnostics (analysis of samples from the patient, preferably blood) has been performed by time consuming laboratory analysis, where it often takes an hour from the sample is taken from the patient to the results is returned to the phycisian. Over the last 10-20 years considerable progress in point-of-care in-vitro diagnostics has been made, where sample analysis is performed near the patient using equipment without the need of specially trained personnel. Still, the equipment is generally expensive and service demanding.
Calmark wants to lead the way globally in the next big development step of diagnostics. Therefore, Calmark has developed a consumable platform containing assays that transform the biomarker of interest to a color (colorimetric assays). Thereafter the results could be read:
- Visually as a semi quantitative “stand-alone test”
- Using the camera function on a smartphone to obtain quantitative results at the point-of-care without any additional analyse equipment besides the users smartphone. See our vision of the diagnostics of the future, view Calmark Prezi Video.
 |
The focus for Calmarks technology at presence is the valid marker of cellular damage Lactate dehydrogenase (LDH) and an emerging biomarker in multiple new clinical situations.
Calmark welcomes you to a world where the physician gets high quality biochemical data about the patient within minutes using a drop of blood, Calmark’s easy-to-use test and a smartphone.
Mathias Karlsson, MD PhD
CEO Calmark Sweden AB
